ProstACT

Product

Last mentioned: Mar 10, 2026

Timeline

  1. Interim Analysis

    Expected interim efficacy data from the larger global patient cohort.

  2. Primary Objectives Met

    Announcement that Part 1 successfully validated safety and dosimetry profiles.

  3. Enrollment Milestone

    Completion of patient enrollment for the Part 1 SELECT lead-in phase.

  4. Study Initiation

    Launch of the ProstACT Global Phase 3 study for mCRPC.

Stories mentioning ProstACT 1

market-trends Bullish

Telix’s ProstACT Phase 3 Hits Primary Goals, Advancing Prostate Cancer Therapy

Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.

4 sources